Citigroup Inc Cellectis S.A. Transaction History

Citigroup Inc

$217 Billion
Q3 2025

A detailed history of Citigroup Inc transactions in Cellectis S.A. stock. As of the latest transaction made, Citigroup Inc holds 990 shares of CLLS stock, worth $3,900. This represents 0.0% of its overall portfolio holdings.

Number of Shares

990

Holding current value

$3,900

% of portfolio

0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	BUY	$1.54 - $3.67 $1,524 - $3,633	990 New	990 $2,000
Q4 2022 Feb 09, 2023	BUY	$1.85 - $2.6 $18 - $26	10 Added 3.95%	263 $0
Q3 2022 Nov 10, 2022	SELL	$2.29 - $4.08 $162 - $289	-71 Reduced 21.91%	253 $1,000
Q2 2022 Aug 10, 2022	SELL	$2.39 - $4.93 $84,663 - $174,640	-35,424 Reduced 99.09%	324 $1,000
Q1 2022 May 12, 2022	SELL	$3.45 - $8.77 $26,875 - $68,318	-7,790 Reduced 17.89%	35,748 $162,000
Q4 2021 Feb 10, 2022	SELL	$8.01 - $12.84 $80,059 - $128,335	-9,995 Reduced 18.67%	43,538 $354,000
Q3 2021 Nov 10, 2021	BUY	$11.94 - $16.09 $639,184 - $861,345	53,533 New	53,533 $675,000

Others Institutions Holding CLLS

# of Institutions

Shares Held

9.46M

Call Options Held

52.7K

Put Options Held

Long Focus Capital Management, LLC San Juan, PR

4.12M
Shares

$16.2 Million
0.43% of portfolio
B Group, Inc. Dallas, TX

3.28M
Shares

$12.9 Million
6.88% of portfolio
Credit Suisse Ag Zurich, V8

1.44M
Shares

$5.67 Million
0.0% of portfolio
Macquarie Group LTD Australia, C3

227K
Shares

$893,887
0.0% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

222K
Shares

$874,518
0.0% of portfolio

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $179M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account